Yamin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yamin Zhang has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Yi Bai
Tianjin First Central Hospital, Tianjin, People’s Republic of China
20 shared publicationsDapeng Chen
First Central Hospital of Tianjin Medical University, Tianjin Medical University
11 shared publicationsWen Tong
Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China
11 shared publicationsPinsheng Han
School of Medicine, Nankai University, Tianjin, People’s Republic of China
10 shared publicationsLiuyang Zhu
Department of Hepatobiliary Surgery, School of Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, China
9 shared publicationsLong Yang
Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China
9 shared publications
Latest Publications
- Open Access
StrongGeneAgent: An Evidence-Grounded Conversational Agent for Gene-Centric Pan-Cancer Multi-Omics Analysis
Background: Single-gene analysis remains a common entry point for investigating cancer biology, yet integrating evidence for a target gene across molecular layers, tumor types, and clinical endpoints remains fragmented across specialized tools and workflows. Here, we present StrongGeneAgent, an evidence-grounded conversational framework for natural-language, gene-centric multi-omics analysis across cancer types. Methods: StrongGeneAgent organizes 64 standardized analytical workflows across 33 TCGA cancer types, spanning transcriptomic, epigenomic, genomic, proteomic, pathway, immune-microenvironment, and pharmacogenomic evidence. Open-ended queries are resolved into molecular entities, cancer contexts, and analytical intents; decomposed when necessary; and routed to compatible deterministic analyses. Quantitative findings are retrieved from structured analytical records rather than generated by the language model, while matched visualizations are produced from the same evidence source, preserving correspondence between questions, estimates, and figures. Results: StrongGeneAgent reproduced the underlying analytical findings in 198 of 200 benchmark questions and maintained high fidelity across repeated, composite, invalid-input, and multi-turn queries. Cross-layer interrogation of CCNB1 in hepatocellular carcinoma demonstrated the integration of expression, clinicopathological variation, survival, protein abundance, and pathway activity around a single molecular target. In a ten-participant usability study, all 50 predefined tasks were completed, with a mean System Usability Scale score of 86.25. Conclusions: StrongGeneAgent provides a scalable interface for transforming single-gene cancer questions into structured, traceable, and interpretable multi-omics evidence across tumor types.
Open AccessStrongGeneAgent: An Evidence-Grounded Conversational Agent for Gene-Centric Pan-Cancer Multi-Omics Analysis
Background: Single-gene analysis remains a common entry point for investigating cancer biology, yet integrating evidence for a target gene across molecular layers, tumor types, and clinical endpoints remains fragmented across specialized tools and workflows. Here, we present StrongGeneAgent, an evidence-grounded conversational framework for natural-language, gene-centric multi-omics analysis across cancer types. Methods: StrongGeneAgent organizes 64 standardized analytical workflows across 33 TCGA cancer types, spanning transcriptomic, epigenomic, genomic, proteomic, pathway, immune-microenvironment, and pharmacogenomic evidence. Open-ended queries are resolved into molecular entities, cancer contexts, and analytical intents; decomposed when necessary; and routed to compatible deterministic analyses. Quantitative findings are retrieved from structured analytical records rather than generated by the language model, while matched visualizations are produced from the same evidence source, preserving correspondence between questions, estimates, and figures. Results: StrongGeneAgent reproduced the underlying analytical findings in 198 of 200 benchmark questions and maintained high fidelity across repeated, composite, invalid-input, and multi-turn queries. Cross-layer interrogation of CCNB1 in hepatocellular carcinoma demonstrated the integration of expression, clinicopathological variation, survival, protein abundance, and pathway activity around a single molecular target. In a ten-participant usability study, all 50 predefined tasks were completed, with a mean System Usability Scale score of 86.25. Conclusions: StrongGeneAgent provides a scalable interface for transforming single-gene cancer questions into structured, traceable, and interpretable multi-omics evidence across tumor types.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-23
DCUN1D5 as a New Biomarker and Regulator of Fatty Acid Metabolism in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with limited reliable biomarkers for early diagnosis and prognosis. In this study, we explored the role of DCUN1D5, a potential biomarker, in HCC. Methods: We performed integrated bioinformatics analyses of publicly available HCC datasets, including TCGA, GEO, and ICGC, followed by in vitro experiments on HCC cell lines to validate our findings. Results: DCUN1D5 expression was significantly elevated in HCC tissues compared to normal liver tissues. High DCUN1D5 levels were associated with poor prognosis and advanced tumor stage in HCC patients. Additionally, bioinformatics analysis revealed a correlation between DCUN1D5 expression levels and both immune infiltration and immunotherapy response in hepatocellular carcinoma. Functional assays revealed that DCUN1D5 knockdown inhibited cell proliferation, migration, and invasion in HCC cells. Mechanistically, Enrichment analysis revealed significant correlations between DCUN1D5 and multiple biological pathways; specifically, we observed a negative correlation between the expression level of DCUN1D5 and fatty acid metabolism. Further cellular experiments demonstrated that knockdown of DCUN1D5 can induce accumulation of free fatty acids in hepatocellular carcinoma cells. Conclusion: In summary, our study identified DCUN1D5 as a potential biomarker for poor prognosis in HCC, high expression of DCUN1D5 are closely associated with tumor invasion and proliferation. Knockdown of DCUN1D5 was found to inhibit the proliferation, migration, and invasion of HCC cells and increases its free fatty acid accumulation. These studies suggest new possibilities for treatment strategies for HCC.
- 1 September 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-23
Open AccessDCUN1D5 as a New Biomarker and Regulator of Fatty Acid Metabolism in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with limited reliable biomarkers for early diagnosis and prognosis. In this study, we explored the role of DCUN1D5, a potential biomarker, in HCC. Methods: We performed integrated bioinformatics analyses of publicly available HCC datasets, including TCGA, GEO, and ICGC, followed by in vitro experiments on HCC cell lines to validate our findings. Results: DCUN1D5 expression was significantly elevated in HCC tissues compared to normal liver tissues. High DCUN1D5 levels were associated with poor prognosis and advanced tumor stage in HCC patients. Additionally, bioinformatics analysis revealed a correlation between DCUN1D5 expression levels and both immune infiltration and immunotherapy response in hepatocellular carcinoma. Functional assays revealed that DCUN1D5 knockdown inhibited cell proliferation, migration, and invasion in HCC cells. Mechanistically, Enrichment analysis revealed significant correlations between DCUN1D5 and multiple biological pathways; specifically, we observed a negative correlation between the expression level of DCUN1D5 and fatty acid metabolism. Further cellular experiments demonstrated that knockdown of DCUN1D5 can induce accumulation of free fatty acids in hepatocellular carcinoma cells. Conclusion: In summary, our study identified DCUN1D5 as a potential biomarker for poor prognosis in HCC, high expression of DCUN1D5 are closely associated with tumor invasion and proliferation. Knockdown of DCUN1D5 was found to inhibit the proliferation, migration, and invasion of HCC cells and increases its free fatty acid accumulation. These studies suggest new possibilities for treatment strategies for HCC.
- Open Access
- 14 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1810794
LGMN+ macrophage promotes the formation of a tumor-supportive microenvironment in gastric cancer
Background: Tumor-associated macrophages (TAMs) are known to facilitate cancer progression. However, the diversity of TAM subsets and their distinct roles in GC remain poorly understood. This study aimed to evaluate the impact of legumain (LGMN) + macrophages on GC progression and clarify the underlying mechanisms of their roles. Methods: We used single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk RNA-seq) analyses from public databases (GEO and TCGA) to systematically evaluate the clinical prognostic significance of LGMN and to characterize the remodeling of its associated signaling pathways. To investigate the role of LGMN in mouse GC (TAMs), we generated macrophage-specific LGMN conditional knockout mice, LGMN flox/flox ; Lyz2-Cre . Utilizing a combination of subcutaneous xenograft tumor models, primary cell isolation and culture, immunofluorescence staining, and tube formation assays, we systematically elucidated the regulatory function and underlying molecular mechanisms of LGMN + macrophages in GC progression. Results: We found that LGMN + macrophages are significantly enriched in GC tissues, and their high infiltration was significantly associated with poor outcomes. Additionally, scRNA-seq revealed that hypoxia and immune suppression pathways are enriched in LGMN + macrophages. LGMN + macrophages infiltration levels showed a significant positive correlation with the infiltration of regulatory T (Treg) cells and endothelial cells. Mechanistically, conditional knockout of LGMN in macrophages inhibits tumor growth by reprogramming TAMs toward an anti-tumor phenotype, reducing Treg cell infiltration, and enhancing the infiltration level of CD8 + T cells. Furthermore, LGMN knockout can inhibit tumor angiogenesis by downregulating VEGF-A expression. Conclusions: LGMN + macrophages drive GC progression by promoting tumor angiogenesis and establishing an immunosuppressive microenvironment. Therefore, targeting this TAM subset may represent a novel therapeutic strategy for GC.
- 14 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1810794
Open AccessLGMN+ macrophage promotes the formation of a tumor-supportive microenvironment in gastric cancer
Background: Tumor-associated macrophages (TAMs) are known to facilitate cancer progression. However, the diversity of TAM subsets and their distinct roles in GC remain poorly understood. This study aimed to evaluate the impact of legumain (LGMN) + macrophages on GC progression and clarify the underlying mechanisms of their roles. Methods: We used single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk RNA-seq) analyses from public databases (GEO and TCGA) to systematically evaluate the clinical prognostic significance of LGMN and to characterize the remodeling of its associated signaling pathways. To investigate the role of LGMN in mouse GC (TAMs), we generated macrophage-specific LGMN conditional knockout mice, LGMN flox/flox ; Lyz2-Cre . Utilizing a combination of subcutaneous xenograft tumor models, primary cell isolation and culture, immunofluorescence staining, and tube formation assays, we systematically elucidated the regulatory function and underlying molecular mechanisms of LGMN + macrophages in GC progression. Results: We found that LGMN + macrophages are significantly enriched in GC tissues, and their high infiltration was significantly associated with poor outcomes. Additionally, scRNA-seq revealed that hypoxia and immune suppression pathways are enriched in LGMN + macrophages. LGMN + macrophages infiltration levels showed a significant positive correlation with the infiltration of regulatory T (Treg) cells and endothelial cells. Mechanistically, conditional knockout of LGMN in macrophages inhibits tumor growth by reprogramming TAMs toward an anti-tumor phenotype, reducing Treg cell infiltration, and enhancing the infiltration level of CD8 + T cells. Furthermore, LGMN knockout can inhibit tumor angiogenesis by downregulating VEGF-A expression. Conclusions: LGMN + macrophages drive GC progression by promoting tumor angiogenesis and establishing an immunosuppressive microenvironment. Therefore, targeting this TAM subset may represent a novel therapeutic strategy for GC.
- Open Access
- 30 March 2026
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 17 (4) , 797-807
Therapeutic Targeting of Oxidative Phosphorylation in Microsatellite Instability-High Gastric Cancer
Background: Gastric cancer is the third leading cause of cancer-related mortality worldwide. According to The Cancer Genome Atlas (TCGA), it can be classified into four molecular subtypes, including microsatellite instability (MSI) and genomically stable (GS) subtypes, which display distinct clinical and pathological features. However, differences in their tumor microenvironment, particularly metabolic reprogramming, remain poorly understood.
- 30 March 2026
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 17 (4) , 797-807
Open AccessTherapeutic Targeting of Oxidative Phosphorylation in Microsatellite Instability-High Gastric Cancer
Background: Gastric cancer is the third leading cause of cancer-related mortality worldwide. According to The Cancer Genome Atlas (TCGA), it can be classified into four molecular subtypes, including microsatellite instability (MSI) and genomically stable (GS) subtypes, which display distinct clinical and pathological features. However, differences in their tumor microenvironment, particularly metabolic reprogramming, remain poorly understood.
- Open Access
- 31 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft
Introduction: Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with a very poor prognosis. How to screen the optimal chemotherapy regimen is crucial for enhancing the prognosis of CCA patients. The study aims to develop patient-derived tumor organoid (PDO) models and patient-derived tumor xenograft (PDX) models of CCA to simulate clinical responses to chemotherapy. Methods: Tumor tissues were collected from patients undergoing surgical resection and subsequently utilized to establish PDO and PDX models. Hematoxylin-eosin (H&E), immunohistology (IHC), and immunofluorescence (IF) were conducted to analyze the biological characteristics of these PDXs and PDOs. Whole exome sequencing (WES) was performed to identify the mutation types of primary tumor, PDO, and PDX. Drug sensitivity assays were conducted utilizing PDO and PDX models to compare clinical treatment responses. Results: In this study, we successfully established 18 PDO (success rate, 56.3%) models and 21 PDX models (success rate, 65.6%) from 32 patients diagnosed with CCA. PDO and PDX preserved the mutational profiles characteristic of the primary tumor samples. The drug screening results from PDOs demonstrated a correlation with the actual clinical response to chemotherapy regimens, and these findings were further validated in PDX models. Conclusions: Our findings indicate that the integration of PDO and PDX models can successfully guide clinical treatment strategies, facilitating effective personalized therapy for CCA patients.
- 31 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessIndividualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft
Introduction: Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with a very poor prognosis. How to screen the optimal chemotherapy regimen is crucial for enhancing the prognosis of CCA patients. The study aims to develop patient-derived tumor organoid (PDO) models and patient-derived tumor xenograft (PDX) models of CCA to simulate clinical responses to chemotherapy. Methods: Tumor tissues were collected from patients undergoing surgical resection and subsequently utilized to establish PDO and PDX models. Hematoxylin-eosin (H&E), immunohistology (IHC), and immunofluorescence (IF) were conducted to analyze the biological characteristics of these PDXs and PDOs. Whole exome sequencing (WES) was performed to identify the mutation types of primary tumor, PDO, and PDX. Drug sensitivity assays were conducted utilizing PDO and PDX models to compare clinical treatment responses. Results: In this study, we successfully established 18 PDO (success rate, 56.3%) models and 21 PDX models (success rate, 65.6%) from 32 patients diagnosed with CCA. PDO and PDX preserved the mutational profiles characteristic of the primary tumor samples. The drug screening results from PDOs demonstrated a correlation with the actual clinical response to chemotherapy regimens, and these findings were further validated in PDX models. Conclusions: Our findings indicate that the integration of PDO and PDX models can successfully guide clinical treatment strategies, facilitating effective personalized therapy for CCA patients.
- Open Access
- 25 December 2025
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
IGF2BP3-STAT3-METTL3 axis promotes malignant progression in hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is often diagnosed in the late stage, with limited effectiveness of traditional treatments and a low overall survival rate.
- 25 December 2025
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Open AccessIGF2BP3-STAT3-METTL3 axis promotes malignant progression in hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is often diagnosed in the late stage, with limited effectiveness of traditional treatments and a low overall survival rate.
- Open Access
Uncovering cantharidin’s mechanism for cholangiocarcinoma treatment using patient-derived tumor organoids
- Open Access
- 1 August 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 50, 525-539
Construction of vascularized liver microtissues recapitulates angiocrine-mediated hepatocytes maturation and enhances therapeutic efficacy for acute liver failure
Liver failure poses a significant challenge for millions of patients. The use of primary human hepatocytes and the engineering of liver organoids or liver tissue provide promising solutions to mitigate the shortage of donor organs. However, insufficient vascularization and functional immaturity remain major barriers impeding optimal functional recovery after transplantation. In this study, adult stem cells derived from human liver tissues were induced to form liver organoids, which were subsequently co-cultured with vascular organoids generated from human induced pluripotent stem cells in a defined ratio to create vascularized liver microtissues. This approach successfully established a complex vascular network analogous to that found in the liver, effectively recapitulating a more physiologically relevant liver architecture. Mechanistically, this configuration promoted the structural and secretory maturation of liver organoids through paracrine signaling from the vasculature. Following transplantation into the mesentery of mice, the vascularized liver microtissues rapidly established connections with the host vasculature and enhanced secretion of albumin into the bloodstream. Moreover, the transplantation of vascularized liver microtissues could effectively ameliorate liver injury and inflammatory responses, reduce apoptosis while promoting cell proliferation in CCl4-induced acute liver failure mice. These findings provide a robust platform for investigating the interactions between vessels and liver, and have important implications for liver failure treatment in the field of regenerative medicine.
- 1 August 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 50, 525-539
Open AccessConstruction of vascularized liver microtissues recapitulates angiocrine-mediated hepatocytes maturation and enhances therapeutic efficacy for acute liver failure
Liver failure poses a significant challenge for millions of patients. The use of primary human hepatocytes and the engineering of liver organoids or liver tissue provide promising solutions to mitigate the shortage of donor organs. However, insufficient vascularization and functional immaturity remain major barriers impeding optimal functional recovery after transplantation. In this study, adult stem cells derived from human liver tissues were induced to form liver organoids, which were subsequently co-cultured with vascular organoids generated from human induced pluripotent stem cells in a defined ratio to create vascularized liver microtissues. This approach successfully established a complex vascular network analogous to that found in the liver, effectively recapitulating a more physiologically relevant liver architecture. Mechanistically, this configuration promoted the structural and secretory maturation of liver organoids through paracrine signaling from the vasculature. Following transplantation into the mesentery of mice, the vascularized liver microtissues rapidly established connections with the host vasculature and enhanced secretion of albumin into the bloodstream. Moreover, the transplantation of vascularized liver microtissues could effectively ameliorate liver injury and inflammatory responses, reduce apoptosis while promoting cell proliferation in CCl4-induced acute liver failure mice. These findings provide a robust platform for investigating the interactions between vessels and liver, and have important implications for liver failure treatment in the field of regenerative medicine.